MEDIA

Sumgen Biotech's Novel ADC Candidate SG2918 For Injection Has Commenced Firs-In-Human Study

Hangzhou, China - December 27, 2023 - Hangzhou Sumgen Biotech Co., Ltd
2023-12-27
Sumgen Biotech's Innovative subcutaneous injectable antibody SG301 SC Has Commenced First-In-Human Study

Hangzhou, China - November 20, 2023 - Hangzhou Sumgen Biotech Co., Ltd (hereinafter referred to as "Sumgen Biotech")
2023-11-20
Sumgen Biotech's First-In-Class ADC SG2918 Has Received IND Clearance From The National Medical Products Administration

Hangzhou, China - October 20, 2023 - Hangzhou Sumgen Biotech Co., Ltd. (hereinafter referred to as "Sumgen Biotech")
2023-10-20

COMPANY HISTORY

2016.10

Beijing R&D Center, Sumgen Monoclonal Antibody (Beijing) Biotech Co., Ltd. Officially established.
2017.12

Sumgen Biotech was selected in“5050 Plan” of Hangzhou High-tech Zone (Binjiang).
2018.06

Sumgen completed Series A financing , Led by Shanghai CCB Equity Investment Management Co., Ltd. as exclusive investor.
2018.09

SG001 obtained NMPA IND approval.
2018.11

Sumgen established partnership for SG001 with CSPC；
Hangzhou CMC R&D center was officially established.
2018.12

Sumgen was designated as 1 of the science and technology SMEs in Zhejiang Province.
2019

Sumgen completed Series A+ Financing, Led by China National Biotech Group (CNBG) as strategic investor.
2020.03

Hangzhou Sumgen Biotech Co., Ltd. and CNBG set up the joint venture CNBG Sumgen Biopharmaceutical (Hangzhou) Co., Ltd. ("CNBG Sumgen") .
2020.08

The construction of an antibody industrialization base was launched.
2020.09

Series B Financing (RMB 220 million) was completed to accelerate product development and industrialization of innovative products.
2020.10

SG301 was approved in US for clinical trial.
2020.11

SG404 was approved for clinical trials in China;
Sumgen was recognized as one of the Top 50 Innovative Biomedicine Enterprises of 2020 in China;
Sumgen was selected as director unit of the Biomedical Innovation Alliance (BIA) of Hangzhou High-tech Zone (Binjiang).
2020.12

Clinical trial of SG404 was initiated at Beijing Cancer Hospital.
2021.02

SG404 was approved by the US FDA for clinical trial.
2021.04

SG12473 obtained IND in both China and the United States;
Sumgen was named of Hangzhou Unicorn Enterprise.
2021.08

First patient was enrolled in the clinical trial of innovative drug SG12473;
SG301 was approved by the CN IND for clinical trial.

PIPELINE

Established Tiered Pipeline of Antibodies for Cancer Treatment.

TECHNOLOGY PLATFORMS

Core Capabilities from Antibody Discovery to Clinical Development.

Copyright Rm. 301, F3, Building C, Block 2, No. 688, Bin'an Road, Changhe Zhejiang ICP Filing No. 18039044